Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Psychosis; Acute
Interventions: risperidone, aripiprazole; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder, Cannabis Abuse
Interventions: Clozapine, Treatment as usual; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 4
States / cities: Los Angeles, California • Kansas City, Missouri • Manchester, New Hampshire + 1 more

Conditions: Schizophrenia
Interventions: Placebo, Bitopertin, Antipsychotics; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 27
States / cities: Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more

Conditions: High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
Interventions: Ziprasidone, aripiprazole, quetiapine, or risperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 13 Years to 18 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Diabetes
Interventions: Intramuscular olanzapine, aripiprazole, Intramuscular aripiprazole, olanzapine; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia
Interventions: Aripiprazole (Abilify®) IM Depot Injection; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 119
States / cities: Dothan, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 97 more

Conditions: Trichotillomania (Hair-Pulling Disorder), Dermatillomania
Interventions: Placebo, Aripiprazole; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psychosis
Interventions: Pattern Separation Paradigm, Sequential Associative Mismatch Paradigm, Encoding Plasticity Paradigm; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years to 35 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Subsyndromal Delirium
Interventions: Haloperidol decanoate, Placebo; Drug
Lead sponsor: Northeastern University; Other
Eligibility: 18 Years to 84 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Diabetes
Interventions: Olanzapine, Aripiprazole; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia, Schizoaffective Disorder, Delusional Disorder
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Schizophrenia
Interventions: SEP-363856; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 16
States / cities: Anaheim, California • Bellflower, California • Garden Grove, California + 12 more

Conditions: Schizophrenia
Interventions: Evenamide, Placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Glendale, California • Gaithersburg, Maryland • Austin, Texas

Conditions: Psychotic Disorders, Schizophrenia
Interventions: risperidone IR and LAI formulation; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Cerritos, California • Santa Ana, California • Atlanta, Georgia

Conditions: Insulin Resistance, Body Composition
Interventions: Depakote (valproate); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Schizophrenia
Interventions: LB-102 (50 mg tablet), LB-102 (100 mg tablet), Placebo; Drug · Other
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 9 more

Conditions: Alcoholism, Sleep Initiation and Maintenance Disorders
Interventions: Quetiapine XR, Placebo.; Drug
Lead sponsor: Subhajit Chakravorty; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Psychosis, Agitation, Delirium
Interventions: ziprasidone, Standard therapy; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Orthostatic Hypotension, Falls
Interventions: Medication review, Nutrition/Salt intake, Education, Exercise, Drug Recommendations; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Schizophrenia
Interventions: Aripiprazole IM Depot; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 12
States / cities: Anaheim, California • Cerritos, California • Garden Grove, California + 9 more

Conditions: Major Depressive Disorder, Anxiety
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 21
States / cities: Tuscon, Arizona • Garden Grove, California • Oceanside, California + 18 more

Conditions: Schizophrenia
Interventions: Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 45 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia, Schizoaffective
Interventions: Consta Club; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Schizophrenia
Interventions: LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more

Search by objective public record fields.

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

Aripiprazole in Body Focused Repetitive Behaviors

Hippocampal Memory Circuits in Delusions

Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol

Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus

An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

Orthostatic Hypotension Treatment on Rehab Unit

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center

A Long-Term, Open-Label, Study on Schizophrenia